Biocon's revenue rises 14% yoy at Rs8,397 crore in FY22; stock marginally up

29 Apr 2022 , 09:27 AM

Biocon Limited, an innovation-led global biopharmaceuticals company, today announced its consolidated financial results for the fourth quarter and the fiscal year ended March 31, 2022.

Company’s Consolidated Revenue jumped 21% yoy to Rs2,476 crore from Rs2,048 crore in Q4FY21. Its EBITDA during the quarter under review stood at Rs659 crore, up by 3% yoy against Rs659 crore in Q4FY21.

Consolidated revenue for FY22 grew 14% to Rs8,397 crore as compared to Rs7,398 crore in FY21. EBIDTA during the financial year under review was reported at Rs2,183 crore as compared to Rs1,907 crore in FY21, logging growth of 14% yoy.

PBT for Q4FY22 stood at Rs384 crore as compared to Rs353 crore in Q4FY21, up by 9% yoy. PBT for FY22 was reported at Rs1094 crore, up by 4% yoy against Rs1055 crore in FY21.

Company reported a PAT of Rs239 crore during Q4FY22 as compared to Rs253 crore in Q4FY21, down by 5.86% yoy. For FY22, PAT came in at Rs648 crore as compared to Rs740 crore in FY21.

FY22 EBITDA Margins came in at 26%, and Q4FY22 EBITDA margin was 27%.

The Board of Directors has recommended a final dividend at the rate of 10% of the face value per share, for the financial year ended March 31, 2022.

Biocon Ltd is currently trading at Rs376.95 up by Rs0.45 or 0.12% from its previous closing of Rs376.50 on the BSE. The scrip opened at Rs379.70.